Annual General Meeting Statement

Cambridge, UK, 26 October 2005 –Minster Pharmaceuticals, the AIM-listed (AIM: MPM) drug development company focused on...

Minster Pharmaceuticals to work with Quintiles on clinical study of Tonabersat

25 October 2005, Cambridge, UK Minster Pharmaceuticals, the AIM-listed (AIM: MPM) drug development company focused on psychiatric and neurological disorders, has signed an...

Minster Pharmaceuticals and the University of Buckingham investigate potential of Sabcomeline in Type 2 Diabetes

14 October 2005, Cambridge, UK Minster Pharmaceuticals, the AIM-listed (AIM: MPM) drug development company, is to have its drug candidate sabcomeline...

Report and Financial Statements 31 March 2005

RII Plc to acquire BioPartners

RII Plc to acquire BioPartners. Raises £3.0 million and seeks Readmission to AIM as Minster Pharmaceuticals plc New money to fund development of drug compounds addressing schizophrenia and migraine; identify further compounds with development potential...

Minster Pharmaceuticals Plc Board Appointment

Minster Pharmaceuticals (the “Company”), the drug development company, announces that today...

Rii shareholders approve EGM resolutions

Shareholders in RII plc today approved resolutions for the company to raise£3.0million, to...

RII Plc to acquire BioPartners

RII Plc to acquire BioPartners. Raises £3.0 million and seeks Readmission to AIM as Minster Pharmaceuticals plc...